Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CSPC Pharma Signs $118.5 Million Deal for Two Molecules from University of Texas

publication date: Jun 26, 2017
CSPC Pharmaceutical of Hong Kong acquired global rights to two pre-clinical drug candidates developed by researchers at University of Texas institutions. The company paid $4.5 million upfront and could pay as much as $114 million in milestones for the rights. A CSPC subsidiary, AlaMab Therapeutics, will be responsible for developing the mAb candidates, which are derived from proteins called connexins and play a role in neuronal and skeletal tissue disease. AlaMab will work to gain approvals of the molecules in the US and China. More details...

Stock Symbol: (HK: 1093)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital